Asianet NewsableAsianet Newsable
4 results for "

Antiviral Pill

"
Mankind Pharma launches cheapest COVID antiviral pill Molnupiravir at Rs 35/capsule, set to hit market soon-dnmMankind Pharma launches cheapest COVID antiviral pill Molnupiravir at Rs 35/capsule, set to hit market soon-dnm

Mankind Pharma launches cheapest COVID antiviral pill Molnupiravir at Rs 35/capsule, set to hit market soon

Mankind Pharma chairman RC Juneja said the full treatment of Molulife (brand name) is expected to cost Rs 1,400 and the brand is set to hit the market this week.

India News Jan 4, 2022, 11:11 AM IST

Pfizer inks deal to allow other companies make and sell its COVID-19 pill in 95 countries-dnmPfizer inks deal to allow other companies make and sell its COVID-19 pill in 95 countries-dnm

Pfizer inks deal to allow other companies make and sell its COVID-19 pill in 95 countries

In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population.
 

World News Nov 16, 2021, 7:15 PM IST

Pfizer antiviral pill cuts severe COVID-19 by 89% in high-risk adults, company to seek FDA nod-dnmPfizer antiviral pill cuts severe COVID-19 by 89% in high-risk adults, company to seek FDA nod-dnm

Pfizer’s antiviral pill reduces severe COVID-19 by 89% in high-risk adults, company to seek FDA nod

The experimental antiviral pill for Covid-19 results appears to surpass those seen with Merck & Co Inc's pill, Molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for Covid-19 patients also at high risk of serious illness.

World News Nov 5, 2021, 8:50 PM IST

Pfizer announces its antiviral pill highly effective cuts risk of severe COVID by 89 pc gcwPfizer announces its antiviral pill highly effective cuts risk of severe COVID by 89 pc gcw

Pfizer announces its antiviral pill highly effective, cuts risk of severe COVID by 89%

Neither company has made the complete trial data available. Pfizer's stock rose 13 per cent to $49.47, while Merck's lost 6 per cent to $84.69.
 

World News Nov 5, 2021, 5:21 PM IST